PYY transgenic mice are protected against diet-induced and genetic obesity by Boey, D et al.
Boey	  et	  al.:	  Neuropeptides	  42	  (2008)	  19-­‐30	  	  
PYY transgenic mice are protected against diet-induced and 
genetic obesity 
 
Dana Boeya, Shu Lina, Ronaldo F. Enriquezb, Nicola J. Leea, Katy Slacka, Michelle 
Couzensa, Paul A. Baldockb, Herbert Herzoga, 1, Amanda Sainsburya 
 
a Neuroscience Research Program, Garvan Institute of Medical Research, St. Vincent’s Hospital, 384 
Victoria Street, Darlinghurst, Sydney NSW 2010, Australia 
b Bone and Mineral Research Program, Garvan Institute of Medical Research, St. Vincent’s Hospital,    
384 Victoria Street, Darlinghurst, Sydney NSW 2010, Australia 
 
Abstract 
 The gut-derived hormone, peptide YY (PYY) reduces food intake and enhances 
satiety in both humans and animals. Obese individuals also have a deficiency in circulating 
peptide YY, although whether this is a cause or a consequence of obesity is unclear. Our 
aims were to determine whether peptide YY (PYY) over-expression may have therapeutic 
effects for the treatment of obesity by altering energy balance and glucose homeostasis. We 
generated PYY transgenic mice and measured body weight, food intake, temperature, 
adiposity, glucose tolerance, circulating hormone and lipid concentrations and hypothalamic 
neuropeptide levels (neuropeptide Y; proopiomelanocortin, and thyrotropin-releasing 
hormone) under chow and high-fat feeding and after crossing these mice onto the genetically 
obese leptin-deficient ob/ob mouse background. PYY transgenic mice were protected against 
diet-induced obesity in association with increased body temperature (indicative of increased 
thermogenesis) and sustained expression of thyrotropin-releasing hormone in the 
paraventricular nucleus of the hypothalamus. Moreover, PYY transgenic mice crossed onto 
the genetically obese ob/ob background had significantly decreased weight gain and 
adiposity, reduced serum triglyceride levels and improved glucose tolerance compared to 
ob/ob controls. There was no effect of PYY transgenic over expression on basal or fasting-
induced food intake measured at 11–12 weeks of age. Together, these findings suggest that 
long-term administration of PYY, PYY-like compounds or agents that stimulate PYY synthesis 
in vivo can reduce excess adiposity and improve glucose tolerance, possibly via effects on 
the hypothalamo–pituitary–thyroid axis and thermogenesis. 
 
1. Introduction 
 Type 2-diabetes mellitus and its complications are affecting increasing numbers of 
people at alarmingly younger ages. This is exacerbated by the current epidemic of obesity, a 
major risk factor for type 2-diabetes. Although weight loss in overweight or obese individuals 
significantly reduces the risk or severity of type 2 diabetes, currently the most effective 
treatments for obesity involve surgical interventions that not only pose medical risks and 
complications, but are also expensive and unfeasible for many, considering these procedures 
are generally performed on subjects with a body mass index over 35. Investigating the 
predisposing and protective factors in the etiology of obesity is vital for finding long-term 
treatments for obesity and reducing the incidence of type 2 diabetes. 
 Gut-derived hormones have been of major interest as possible targets for the 
treatment of obesity in light of their marked effects on satiety and food intake. One of these 
hormones is peptide YY (PYY), which belongs to a family of peptides including neuropeptide 
Y (NPY) and pancreatic polypeptide (PP), all of which are known to have potent effects on 
feeding and energy balance via their unique interactions with G-protein-coupled Y receptors 
(Y1, Y2, Y4, Y5, y6) (Blomqvist and Herzog, 1997, Stanley et al., 1986 and Ueno et al., 
1999). 
 PYY is predominantly produced by endocrine L cells of the lower gastrointestinal tract 
and is also expressed in alpha cells of the islets of Langerhans as well as in the stomach and 
brainstem (Pieribone et al., 1992). Two forms of PYY exist in the circulation: the full length 
PYY1-36, and the shortened form PYY3-36, cleaved from secreted PYY1-36 by the cell 
surface enzyme dipeptidyl peptidase IV (Lundberg et al., 1982). PYY1-36 binds to all known 
Y receptors, albeit to each with differing affinities, whereas PYY3-36 preferentially binds the 
Y2 receptor and to a lesser extent the Y5 receptor (Blomqvist and Herzog, 1997). Obese 
subjects have significantly reduced circulating levels of PYY (Batterham et al., 2003). 
Moreover, it has been suggested that this is due to a deficiency in PYY release from the colon 
(Le Roux et al., 2005). In light of these observations, and considering that low fasting serum 
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PYY levels are seen in non-obese subjects with a high genetic predisposition towards 
subsequent development of obesity on account of a family history of type 2 diabetes mellitus 
(Boey et al., 2006a), it is likely that low levels of circulating PYY may not simply be a 
consequence of obesity but a predisposing factor to the development of obesity. 
 Recent studies have demonstrated acute affects of PYY1-36 and PYY3-36 in 
inhibiting food intake in animals and in man (Adams et al., 2004, Batterham et al., 2002, 
Challis et al., 2003, Chelikani et al., 2004, Chelikani et al., 2005, Halatchev et al., 
2004 and Riediger et al., 2004). It is thought that after a meal, PYY3-36, the main form of 
PYY circulating postprandially, acts on the arcuate nucleus of the hypothalamus. Specifically, 
PYY3-36 binds to Y2 receptors on NPY neurones, thereby inhibiting the orexigenic effect of 
these neurons and indirectly stimulating the action of anorexigenic neurons producing POMC 
(proopiomelanocortin, the precursor to the anorexigenic alpha melanocyte stimulating 
hormone) (Batterham et al., 2002). In contrast, other work has suggested that PYY3-36 not 
only acts via Y2 receptors to inhibit NPY neurones but also directly inhibits POMC neurones 
via Y2 receptors (Acuna-Goycolea and van den Pol, 2005 and Fetissov et al., 2004). In light 
of these findings, it has been proposed that the PYY3-36-mediated inhibition of food intake 
occurs primarily through the inhibition of NPY neurones. Other studies also show that 
intraperitoneally injected PYY3-36 activates neurones in the area postrema and nucleus 
tractus solitarius in rodents, which may be another mechanism by which PYY3-36 influences 
food intake (Bonaz et al., 1993 and Halatchev and Cone, 2005). 
 PYY appears to play a long-term role in regulating food intake, body weight and body 
composition. A four-week continuous infusion of PYY3-36 in diet-induced obese mice 
reduced cumulative food intake, weight gain and adiposity (Pittner et al., 2004). In ob/ob mice 
and fa/fa rats, on the other hand, four-week continuous infusion of PYY3-36 decreased body 
weight gain in association with a transient reduction in food intake observed during the first 4 
days of infusion only ( Pittner et al., 2004). These findings suggest that PYY may also 
influence body weight and body composition via effects independent of changes in food 
intake. Indeed, seven day subcutaneous administration of PYY3-36 to diet-induced obese 
mice transiently reduced food intake and also led to maintenance of mass-specific energy 
expenditure despite concurrent anorexia, reduced respiratory quotient (indicating increased 
fat oxidation) and led to significantly decreased adiposity (Adams et al., 2006). Moreover, we 
and others have previously shown that PYY ablation results in obesity in mice ( Batterham et 
al., 2006 and Boey et al., 2006b). 
 Collectively, these studies suggest that PYY plays a major role in influencing long-
term energy balance via effects on food intake and possibly also on metabolic processes, and 
that long-term elevation of PYY levels may attenuate obesity. However, studies investigating 
the effects of PYY administration have been limited to a maximum of 4-week duration, which 
is also not representative of PYY secretion in vivo. Furthermore, the mechanisms underlying 
PYY-induced effects on food intake, metabolic rate, body weight and adiposity have not yet 
been elucidated. Answers to these caveats are of relevance to human health since 
pharmacological treatments for obesity are administered for months, not weeks, and because 
new obesity treatments may involve enhancing endogenous PYY release with meals or 
episodic dosing strategies. 
 In order to test the hypothesis that elevated PYY might result in long-term reductions 
in food intake, body weight and adiposity, we generated PYY transgenic mice to over-express 
murine PYY. These mice were studied under chow fed conditions as well as under diet- and 
genetically induced obesogenic conditions to determine whether long-term endogenous PYY 
over-expression may have an anti-obesity effect. Moreover, we aimed to elucidate 
mechanisms for any possible effects of PYY over-expression on energy homeostasis by 
investigating thermogenesis, the hypothalamo–pituitary–thyroid axis as well as glucose 
homeostasis. 
 
2. Research design and methods 
2.1. PYY transgenic mouse generation 
 All research and animal care procedures were approved by the Garvan Institute/St. 
Vincent’s Hospital Animal Experimentation Ethics Committee. A 129/SvJ mouse genomic 
BAC clone containing the PYY gene and flanking sequences was obtained from Prof. 
Dominic Withers (UCL, UK). The 130 kb clone was mapped and various fragments 
subcloned. A 10.5 kb SpeI fragment containing 6 kb 5′-flanking sequence, the entire PYY 
gene and 3 kb 3′-flanking sequence was chosen as the transgene construct (Fig. 1A). In order 
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to identify the transgene the NsiI restrictions site in the position 9832 of the SpeI fragment 
was mutated to a BglII restriction site. A 300 bp probe for screening located between 
nucleotides 7470 and 7770 of the SpeI fragment was generated by PCR. Purified DNA of the 
modified SpeI fragment was injected into oozytes from C57BL/6 mice and reintroduced into 
pseudo-pregnant mice. Southern analysis of DNA obtained from tail tips of offspring from 
these mice revealed two positive founders carrying the PYY transgene. Wild type C57/BL6 
mice were used as controls (Animal Resource Centre, Perth, Australia). 
	  	  
 Mice genotype was confirmed on DNA obtained from tail tips with PCR using the 
combination of oligonucleotides mPYY-R (5′-GGTACAAGTATGTGTAGGTGC-3′) and mPYY-
S (5′-GAACTCACTCTGTAGACCAG-3′). The conditions for all PCR analyses were 35 cycles 
of 94 °C for 45 s, 58 °C for 1 min and 63 °C for 1 min. Insertion of the Bgl2 site was confirmed 
by digesting the PCR product overnight with restriction enzyme Bgl2. Mice genotype was also 
confirmed by Southern blot analysis of Bgl2 digested DNA employing a probe generated by 
PCR using oligonucleotidess mPYY-G (5′-GAATTCCCTGTAATGCTG-3′) and mPYY-H (5′- 
CCCTCCAAGACCTAGGAAA-3′). All of the mice used in experiments were shown by both 
PCR and Southern blot analysis to carry the PYY transgene. 
 PYY transgenic mice were also crossed onto mice of mixed C57BL/6/129/SvJ 
background, heterozygous for the ob/ob gene (Jackson Laboratories, ME, USA). 
Homozygosity of the ob locus in ob/ob mice was confirmed using PCR with oligonucleotides 
mOb-2 (5′-GAGTCAAGCATTGTGGAGT-3′) and mOb-3 (5′-CAGTCGGTATCCGCCAAG-3′) 
using 35 cycles of 94 °C for 45 s, 61 °C for 1 min and 72 °C for 25 s followed by digestion 
with the restriction enzyme Ddel (Roche Diagnostics, Mannheim, Germany) at 37 °C 
overnight. 
 
2.2. Staining and measurement of PYY positive cells 
 Whole pancreas and segments of the colon were fixed and stained for PYY as 
described previously (Boey et al., 2006b). Six to eight random pancreatic sections obtained 
from whole pancreas from four male wild type and 4 PYY transgenic mice were stained for 
PYY. Briefly, tissues fixed in 4% paraformaldehyde (PFA) in PBS overnight at 4 °C were 
transferred to 70% ethanol before being processed and embedded in paraffin. Sections 
(7 µm) were cut and mounted onto charged slides. Sections were deparaffinised in xylene 
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Fig. 1. Generation of PYY transgenic mice. PYY transgene construct and screening strategy. (A) A 10 kb SacI fragment (bold line) containing the
entire mouse PYY gene is used as a transgene. For screening purposes, an Nsi I site has been mutated to a Bgl II site distinguishing between the 14 kb
WT band and the 7.2 kb transgene band when Probe A is used. (B) Southern analysis of DNA from PYYtgmice. Positive transgenic mice exhibit the
14 and 7 kb fragment. (C) Representative pictures of GAPDH and PYY expression in wild type and PYYtg mice using RT-PCR.
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and rehydrated from 100% ethanol to water. Slides were incubated in 1% H2O2 in methanol 
for 20 min, rinsed in PBS and blocked with 20% normal goat serum in PBS for 20 min. 
Excess blocking solution was removed before applying the rabbit anti-human PYY antiserum 
(Peninsula Laboratories, CA, USA) (1:1000) for 1 h at room temperature. Slides were rinsed 
in PBS before incubation with goat anti-rabbit IgG-horse radish peroxidase conjugated 
antibody (Zymed Laboratories, San Francisco, CA, USA) (1:1000) for 30 min at room 
temperature. Slides were washed in PBS and treated with the diaminobenzidine DAKO 
(Carpinteria, CA, USA) for 5 min. Slides were rinsed in water, counterstained in haematoxylin 
(30 s), rinsed in water, dipped in lithium carbonate and rinsed in water again. Sections were 
dehydrated through graded ethanols and xylene before coverslipping. Using a ProgRes 3008 
camera (Zeiss, Jena, Germany) mounted on a Zeiss Axiophot microscope, the number of 
PYY positive cells per islet was counted using a 20× objective lens. Islet size was determined 
using Leica IM 1000 version 1.20 software (Leica Microsystems, Heerbrig, Switzerland). The 
average number of PYY positive cells per mm2 islet was calculated. 
 
2.3. Reverse transcriptase PCR 
 Whole mouse colon rapidly excised from animals killed by cervical dislocation at 
10:00–12:00 h was cleaned and immediately frozen in liquid nitrogen. Total RNA was 
extracted using Trizol (Invitrogen, CA, USA) according to the manufacturer’s instructions. 
RNA was treated with DNase (Promega, Madison, USA) prior to RNeasy Mini clean-up 
(Qiagen, Victoria, Australia) following the manufacturers protocol. RNA quality and 
concentration was determined using the Agilent 2100 bioanalyser (Agilent Technologies, Palo 
Alto, CA, USA). 
 Total RNA (1 µg) was denatured at 65 °C for 5 min in the presence of 1 µl oligo(dT)20 
and 1 µl dNTP, and cDNA was synthesized according to the manufacturers instructions 
(Invitrogen, CA, USA). 
 GAPDH and PYY expression were determined using RT-PCR. In brief, a 25 µl PCR 
reaction volume containing cDNA (1 µl), 0.25 µl primers for GAPDH (Forward 5′ 
ACTTTGTCAAGCTCATTTCC 3′; Reverse 5′ TGCAGCGAACTTTATTGATG 3′) or PYY 
(Forward 5′ ACGGTCGCAATGCTGCTAAT 3′; Reverse 5′ AAGGGGAGGTTCTCGCTGTC) 
(100 pmol/µl), 2.5 µl 10xPCR Buffer, 3 µl MgCl2, 0.25 µl dNTPs (25 mM), 0.5 µl Taq 
polymerase (Roche Diagnostics, Castle Hill, NSW) made up to 25 µl with water was reacted 
using conditions starting with 94 °C for 5 min followed by the optimized conditions (GAPDH: 
94 °C for 40 s, 57 °C 40 s, 72 °C 45 s, 25 cycles; PYY: 94 °C for 40 s, 65 °C 40 s, 72 °C 45 s, 
30 cycles). 
 
2.4. Measurement of food intake and bodyweight 
 Male C57/BL6 wild type, PYYtg, ob/ob (a gift from M. Cleasby, Garvan Institute, 
Sydney Australia) and PYYtg/ob animals originating from three to four different breeding pairs 
were housed under conditions of controlled temperature (22 °C) and illumination (12 h light 
cycle, lights on at 07:00 h) (n = 6–12). Unless otherwise stated, all mice were fed a normal 
chow diet ad libitum (6% calories from fat, 21% calories from protein, 71% calories from 
carbohydrate, 2.6 kcal/g, Gordon’s Speciality Stock Feeds, Yanderra, NSW, Australia). One 
group of wild type and PYYtg mice were fed a high fat diet (46% calories from fat, 21% 
calories from protein, 33% calories from carbohydrate, 4.72 kcal/g) from 4 to 5 weeks of age 
onwards. The high fat diet, made in-house, was based on the composition of Rodent Diet 
Catalogue Number D12451 (Research Diets, New Brunswick, NJ), with the exception that 
safflower oil and copha were used in place of soybean oil and lard, respectively. Body weight 
was monitored weekly. At 11 weeks of age, non-fasted food and water intake were measured 
over four consecutive days in individually housed mice. Actual food intake was calculated as 
the weight of pellets taken from the food hopper minus the weight of food spilled in the cage. 
The weight of spilled food was determined as the 24-h increase in weight of the cage 
bedding, after removing all feces and air-drying to eliminate weight changes due to urine and 
water bottle drips. At 12 weeks of age, mice were fasted for 24 h and the amount of food 
removed from the hopper was measured at 1, 2, 8, 24, 48 and 72 h after re-introduction of 
food. Actual food intake was determined as described above after 24, 48 and 72 h of re-
feeding, and body weight was tracked at the same time each day before and after the 24-h 
fast. 
 
2.5. Temperature measurements 
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 Rectal temperature was measured at 16:00 h for 3 days consecutively in 10-week-old 
mice. PYYtg and wild type mice were placed in a hinged restraining cylinder and a rectal 
temperature probe (Physitemp Instruments, NJ, USA) attached to the BAT-10 Multipurpose 
Thermometer (Physitemp Instruments, NJ, USA) was inserted and left in place until the 
temperature reading stabilized. Temperatures were measured in PYYtg/ob and ob/ob mice 
without a hinged restraining cylinder due to size. 
 
2.6. Glucose tolerance tests 
 At 13 weeks of age, mice were fasted for 24 h prior to intraperitoneal glucose 
tolerance tests (1 g/kg). Serial blood samples were collected from the tail for determination of 
serum glucose and insulin levels. Area under the curve (AUC) was calculated between 0 and 
120 min after glucose injection and expressed as mM glucose per minute. 
 
2.7. Tissue collection and analysis 
 Wild type, PYYtg, ob/ob and PYYtg/ob mice (16 weeks of age) were killed by cervical 
dislocation and decapitation between 12:00 and 14:00 h for collection of trunk blood. Brains 
were immediately removed and frozen on dry ice. White adipose tissue depots (right inguinal, 
right epididymal or periovarian (gonadal), right retroperitoneal and mesenteric) were removed 
and weighed. 
 
 2.8. Serum analyses 
Total serum PYY concentrations were determined using a radioimmunoassay kit from 
Phoenix Pharmaceuticals, Belmont, CA, USA as previously described (Boey et al., 2006a). 
Serum glucagon levels were measured by radioimmunoassay kits from Linco Research (St. 
Louis, MO, USA), insulin levels were measured using an ELISA Kit from Mercodia (Uppsala, 
Sweden) or Linco Research, serum free T4 and testosterone concentrations were measured 
with kits from ICN Biomedicals (Costa Mesa, CA, USA), serum IGF-1 was determined using 
an RIA Kit from Bioclone (Marrickville, NSW, Australia), serum glucose was determined with a 
glucose oxidase assay kit (Trace Scientific, Melbourne, Australia), and serum triglyceride and 
free fatty acid levels were determined with kits from Roche Diagnostics, Mannheim, Germany 
and Wako, Osaka, Japan, respectively. 
 
 2.9. In situ hybridization 
Coronal brain sections (20 µm) were cut on a cryostat (Leica CM3050S, Leica, Wetzlar, 
Germany) and thaw-mounted on Superfrost® slides (Menzel-Glaser, Braunschweig, 
Germany). Matching sections from the same coronal brain area of PYY transgenic and wild 
type mice (five mice per group) were assayed together using DNA oligonucleotides 
complementary to mouse NPY (5′-GAGGGTCAGTCCACACAGCCCCATTCGCTTGTTA- 
CCTAGCAT-3′); mouse POMC (5′-TGGCTGCTCTCCAGGCACCAGCTCCACACATCTA- 
TGGAGG-3′); and mouse thyrotropin-releasing hormone (TRH; 5′-AACCTTACTCCTCCA- 
GAGGTT CCCTGACCCAGGCTTCCAGTTGTG-3′) as described previously (Sainsbury et al., 
2002). NPY and POMC expression were determined in the arcuate nucleus and TRH was 
determined in the paraventricular nucleus of the hypothalamus. 
 For evaluation of mRNA levels in scattered neurons, images from dipped sections 
were digitized using a ProgRes 3008 camera (Zeiss, Jena, Germany) mounted on a Zeiss 
Axiophot microscope. Silver grain density over single neurons was evaluated using NIH-
Image 1.61 software (written by Wayne Rasband and available at zippy.nimh.nih.gov). 
Background labeling was uniform and never exceeded 5% of specific signal. 
 
2.10. Statistical analyses 
 Analyses were done using two-factor ANOVA to assess differences due to genotype 
and diet. When the effect of genotype was significant, or when there was a significant 
genotype-diet interaction effect, Fisher’s post hoc tests were used to determine differences 
amongst groups. Results for body weight, lean and fat mass, food intake and differences in 
serum glucose and insulin levels during glucose tolerance tests were compared among 
groups using two-factor repeated measures ANOVA followed by Fisher’s post hoc tests. 
StatView version 4.5 (Abacus Concepts Inc., CA, USA) was used for all statistical analyses 
and p < 0.05 was accepted as being statistically significant. 
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3. Results 
3.1. Increased embryonic lethality in PYY transgenic mice 
 Of the 150 offspring derived from oozytes injected with a construct containing the 
murine PYY gene under its endogenous mouse promoter, only two mice carrying the PYY 
transgene were identified by southern blot analyses ( Fig. 1B). The low success rate in 
obtaining PYY over-expressing mice suggests that strong expression of PYY may be 
embryonic lethal, which has been confirmed by a recent report that CMV driven PYY 
overexpression in embryonic life leads to neural tube defects (Yuzuriha et al., 2007). RT-PCR 
confirmed the over-expression of PYY mRNA in our PYY transgenic mice (Fig. 1C). Serum 
concentrations of PYY were elevated in fat-fed transgenic mice (40.6 ± 5.9 pM versus 
24.4 ± 2.8 pM in fat-fed wild types, means ± SEM of 3–5 mice per group), albeit this 
difference did not reach statistical significance. Nevertheless, quantification of alpha cells in 
the islets of Langerhan, known to produce PYY (Lundberg et al., 1982), clearly demonstrated 
that under conditions of high-fat feeding, the number of PYY-positive alpha cells in the islets 
of Langerhans was significantly higher in PYY transgenic mice compared to wild type mice 
(Table 1). In this regard it is noteworthy that high-fat feeding increases alpha cell size, volume 
and number (Cerf et al., 2005). 
 
3.2. Attenuated diet-induced obesity in PYYtg mice with no effects on food intake 
 There has been controversy as to whether exogenously administered PYY reduces 
food intake in mice (Tschop et al., 2004). Moreover, there have been limitations in elevating 
PYY levels using osmotic mini-pumps because this mode of administration does not mimic 
the secretion of PYY in vivo ( Pittner et al., 2004). We therefore investigated food intake as 
well as body weight and adiposity in PYYtg mice. Under chow feeding, body weight ( Fig. 2A), 
basal and fasting-induced food intake measured at 11–12 weeks of age (Table 1, Fig. 3A) 
and adiposity (Fig. 2D and F) were comparable between wild type and PYY transgenic 
animals. Interestingly, under high-fat feeding PYY transgenic mice showed no significant 
difference in body weight (Fig. 2B) but were significantly less fat (Fig. 2D and F) and had a 
significantly higher body temperature (Fig. 2H) than fat-fed wild types in the absence of 
changes in basal or fasting-induced food intake measured at 11–12 weeks of age (Table 1, 
Fig. 3B). This increase in temperature suggests that the reduced adiposity observed in high-
fat fed PYY transgenic compared to fat-fed wild type mice was attributed by an increase in 
thermogenesis. In keeping with their lack of change in food intake compared to wild type 
values, PYYtg mice were no different from wild types with respect to water intake ( Table 1). 
High fat-fed PYYtg mice lost significantly less body weight than controls after a 24-h fast 
compared to wild type ( Fig. 3D). 
 
3.3. Increased activity of the hypothalamo–pituitary–thyroid axis in PYY transgenic mice 
 In order to determine whether the decreased fat mass in PYYtg mice was 
accompanied by changes in circulating lipids, free fatty acid and triglyceride levels in PYY 
transgenic animals on a high-fat diet were analysed. PYYtg mice exhibited significantly lower 
serum free fatty acid and triglyceride levels in comparison with transgenic animals on a chow 
diet ( Table 1), although chow-fed PYY transgenics on a lean background had higher serum 
free fatty acid and triglyceride levels than chow-fed wild type controls (Table 1). Circulating 
thyroid hormone levels (free T4) were also measured as an indication of activity of the 
hypothalamo–pituitary–thyroid axis, an important regulator of thermogenesis and metabolic 
rate (Ribeiro et al., 2001). Unlike wild type animals, which showed significantly higher serum 
free T4 levels on a high-fat diet compared to a chow diet, no such increase in circulating free 
T4 levels was seen in transgenic mice with high fat feeding (Table 1). There were no 
differences in serum concentrations of glucagon, testosterone, glucose or insulin between 
wild type and PYYtg animals under conditions of chow- or high fat feeding ( Table 1). 
Interestingly, under chow-fed conditions, serum IGF-1 levels were significantly lower in PYYtg 
animals than in wild types ( Table 1). 
 
3.4. PYY transgenic mice have increased thyrotropin-releasing hormone (TRH) expression in 
the paraventricular nucleus of the hypothalamus 
 To assess possible central mechanisms for the decreased adiposity and increased 
thermogenesis observed in PYYtg mice, we measured central expression of peptides known 
to regulate energy balance (TRH, NPY and POMC). Under chow-fed conditions, TRH levels 
in the paraventricular nucleus were similar between PYYtg and wild type animals ( Table 2). 
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However, although TRH levels were significantly reduced by high-fat feeding in wild type 
animals, TRH levels in PYY transgenic animals were unaffected by diet and were significantly 
higher in high-fat fed PYYtg mice compared with high-fat fed wild types ( Table 2). 
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nously administered PYY reduces food intake in mice
(Tschop et al., 2004). Moreover, there have been limita-
tions in elevating PYY levels using osmotic mini-pumps
because this mode of administration does not mimic the
secretion of PYY in vivo (Pittner et al., 2004). We there-
fore investigated food intake as well as body weight and
adiposity in PYYtg mice. Under chow feeding, body
weight (Fig. 2A), basal and fasting-induced food intake
measured at 11–12 weeks of age (Table 1, Fig. 3A) and
adiposity (Fig. 2D and F) were comparable between
wild type and PYY transgenic animals. Interestingly,
under high-fat feeding PYY transgenic mice showed
no significant diﬀerence in body weight (Fig. 2B) but
were significantly less fat (Fig. 2D and F) and had a
significantly higher body temperature (Fig. 2H) than
fat-fed wild types in the absence of changes in basal or
fasting-induced food intake measured at 11–12 weeks
of age (Table 1, Fig. 3B). This increase in temperature
suggests that the reduced adiposity observed in high-
fat fed PYY transgenic compared to fat-fed wild type
mice was attributed by an increase in thermogenesis.
In keeping with their lack of change in food intake com-
pared to wild type values, PYYtg mice were no diﬀerent
from wild types with respect to water intake (Table 1).
High fat-fed PYYtg mice lost significantly less body
weight than controls after a 24-h fast compared to wild
type (Fig. 3D).
3.3. Increased activity of the hypothalamo–pituitary–
thyroid axis in PYY transgenic mice
In order to determine whether the decreased fat mass
in PYYtg mice was accompanied by changes in circulat-
ing lipids, free fatty acid and triglyceride levels in PYY
transgenic animals on a high-fat diet were analysed.
PYYtg mice exhibited significantly lower serum free
fatty acid and triglyceride levels in comparison with
transgenic animals on a chow diet (Table 1), although
chow-fed PYY transgenics on a lean background had
higher serum free fatty acid and triglyceride levels than
chow-fed wild type controls (Table 1). Circulating thy-
roid hormone levels (free T4) were also measured as
an indication of activity of the hypothalamo–pitui-
tary–thyroid axis, an important regulator of thermogen-
esis and metabolic rate (Ribeiro et al., 2001). Unlike
wild type animals, which showed significantly higher
serum free T4 levels on a high-fat diet compared to a
chow diet, no such increase in circulating free T4 levels
was seen in transgenic mice with high fat feeding (Table
1). There were no diﬀerences in serum concentrations of
glucagon, testosterone, glucose or insulin between wild
type and PYYtg animals under conditions of chow- or
Table 1
The number of PYY-positive cells in the pancreatic islets of Langer-
han, food and water intake and serum parameters of chow and high
fat-fed wild type and PYY transgenic mice on a lean or obese (ob/ob)
background. Data represents means ± SEM of 8–12 mice per group
Wild type PYYtg
PYY positive cells/size of islet (mm2)
Chow 39.4 ± 2.3 39.8 ± 3.8
High-fat 48.9 ± 2.6 58.1 ± 5.8!
Food Intake/24 h (g)
Chow 4.5 ± 0.3 4.7 ± 0.1
High-fat 3.4 ± 0.5 2.9 ± 0.1
ob/ob 7.3 ± 0.5 7.2 ± 0.5
Water Intake/ 24 h (g)
Chow 6.3 ± 0.4 5.7 ± 0.3
High-fat 3.1 ± 0.2 3.5 ± 0.2
ob/ob 7.7 ± 0.9 6.2 ± 0.6
Free fatty acids (mM)
Chow 1.6 ± 0.1 1.9 ± 0.1**
High-fat 1.9 ± 0.1* 1.6 ± 0.1!
ob/ob 1.6 ± 0.1 1.6 ± 0.1
Triglycerides (mM)
Chow 0.91 ± 0.15 1.83 ± 0.15***
High-fat 1.38 ± 0.22 1.22 ± 0.18!
ob/ob 23.6 ± 1.9 13.8 ± 0.7**
Free T4 (pmol/l)
Chow 20.9 ± 1.58 20.0 ± 1.8
High-fat 31.23 ± 8.69* 22.55 ± 2.43
Glucagon (pM)
Chow 25.9 ± 4.6 31.4 ± 6.7
High-fat 22.2 ± 5.1 37.0 ± 6.2
Testosterone (nM)
Chow 10.8 ± 3.3 14.7 ± 10.0
High-fat 21.5 ± 7.2 15.7 ± 8.0
Glucose (mM)
Chow 10.4 ± 0.4 9.1 ± 0.4
High-fat 9.7 ± 0.7 9.0 ± 0.4
Insulin (pM)
Chow 230.0 ± 19.3 324.9 ± 56.5
High-fat 311.1 ± 63.5 311.8 ± 36.1
IGF-1 (ng/ml)
Chow 35.34 ± 2.62 26.75 ± 4.32*
High-fat 33.51 ± 2.53 27.53 ± 1.00
* p < 0.05.
** p < 0.01.
*** p < 0.001 versus chow-fed wild type mice.
! p < 0.05 versus chow-fed PYYtg mice.
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high fat feeding (Table 1). Interestingly, under chow-fed
conditions, serum IGF-1 levels were significantly lower
in PYYtg animals than in wild types (Table 1).
3.4. PYY transgenic mice have increased thyrotropin-
releasing hormone (TRH) expression in the
paraventricular nucleus of the hypothalamus
To assess possible central mechanisms for the
decreased adiposity and increased thermogenesis
observed in PYYtg mice, we measured central expres-
sion of peptides known to regulate energy balance
(TRH, NPY and POMC). Under chow-fed conditions,
TRH levels in the paraventricular nucleus were similar
between PYYtg and wild type animals (Table 2).
However, although TRH levels were significantly
reduced by high-fat feeding in wild type animals,
TRH levels in PYY transgenic animals were unaf-
fected by diet and were significantly higher in high-
fat fed PYYtg mice compared with high-fat fed wild
types (Table 2).
Under chow-fed conditions, expression of NPY in the
arcuate nucleus of the hypothalamus was 16% higher in
PYY transgenic mice compared to wild types, albeit the
diﬀerence was not significant, and there was no change
in POMC expression observed between the chow-fed
groups (Table 2). NPY and POMC expression were
not diﬀerent between high-fat fed groups (Table 2).
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Fig. 2. Body weight, adiposity and thermogenesis in PYYtg mice. Bodyweight curves for male wild type and PYY transgenic mice fed a chow diet
(A) or high fat diet (B) or crossed on the ob/ob background (C). Data represents means ± SEM of 6–12 mice per group. *p < 0.0001 versus the growth
curve for ob/ob mice. Weight of the summation of (D + E) white adipose tissue depots, (F + G) brown adipose tissue depots represented as absolute
values or as percentage of body weight (%BW), and (H + I) temperatures of chow- and high fat-fed wild type and PYY transgenic mice and PYYtg/
ob and ob/ob mice. Data represents means ± SEM of 8–12 mice per group. *p < 0.05, **p < 0.01 ***p < 0.001 versus the comparison shown by
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3.5. PYY transgenic expression results in decreased body
weight and adiposity in leptin deficient mice
As PYY transgenic mice were protected against the
development of diet-induced obesity, we were interested
in determining the eﬀect of PYY over-expression on a
genetic model of obesity, using ob/ob mice. PYYtg/ob
mice had a significantly lower body weight than ob/ob
controls (Fig. 2C). Similar to high-fat fed PYYtg mice,
PYYtg/ob mice had significantly less white adipose tis-
sue both in absolute terms (data not shown) and as a
percent of body weight (Fig. 2E) and an increased body
temperature (Fig. 2I) than ob/ob controls, in the absence
of changes in basal and fasting-induced food intake
(Table 1, Fig. 3C). Consistent with the lack of eﬀect of
the PYY transgene on food intake, water intake of
PYYtg/ob mice was no diﬀerent from that of ob/ob mice
(Table 1). However, PYYtg/ob mice showed significantly
lower serum triglyceride levels than ob/ob controls
(Table 1), in keeping with the associated decrease in
fat mass (Fig. 2E). This demonstrates that PYYtg mice
have reduced weight and body fat via eﬀects indepen-
dent of food intake.
3.6. PYYtg/ob mice exhibit improved glucose tolerance
In light of our previous findings that PYY ablation
results in basal and glucose-induced hyperinsulinemia
and glucose intolerance (Boey et al., 2006b), we hypoth-
esized that PYYtg mice would have improved glucose
tolerance. Surprisingly, under conditions of chow- and
high-fat feeding, fasting serum glucose levels were signif-
icantly higher in PYYtg compared to wild type mice
(Fig. 4A and B). However, serum glucose levels, glucose
area under the curve and serum insulin levels during a
glucose tolerance test were not significantly diﬀerent
between chow- or fat-fed transgenic and wild type ani-
mals on a lean background (Fig. 4A + B, D + E, and
G + H).
As PYYtg/ob mice showed decreased body weight
and fat mass, we hypothesized that PYY over-expres-
sion may have additional beneficial eﬀects on the hyp-
einsulinemia, hyperglycemia and insulin resistance
exhibited by ob/ob mice. In keeping with this, PYYtg/
ob mice had significantly lower fasting serum glucose
levels and were markedly more glucose tolerant than
ob/ob animals during the glucose tolerance test
(Fig. 4C + F). PYYtg/ob mice also exhibited lower
serum insulin levels for the duration of the glucose toler-
ance test (Fig. 4I).
4. Discussion
This study demonstrates the important role PYY has
in the regulation of energy homeostasis, since even only
modestly increased expression of PYY can significantly
reduce body weight and/or adiposity under diet- and
genetically-induced obesogenic conditions. This is asso-
ciated with significantly improved glucose tolerance in
genetically obese ob/ob mice, changes in the hypothal-
amo–pituitary–thyroid axis and increased thermogenic
activity. Resistance to diet- or genetically-induced obes-
ity in PYYtg mice occurred in the absence of significant
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Fig. 3. Fasting-induced food intake and body weight in PYYtg mice.
The fasting-induced food intake of chow-fed wild type and PYYtg
mice (A), high fat-fed wild type and PYYtg mice (B) and chow-fed ob/
ob and PYYtg/ob mice (C). (D) Percentage body weight loss after a 24
hour fast in chow-fed and high fat-fed lean and obese wild type and
PYYtg animals. Data represents means ± SEM of 7–12 mice per
group. ***p < 0.001 versus the comparison shown by horizontal bars.
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Under chow-fed conditions, expression of NPY in the arcuate nucleus of the hypothalamus 
was 16% higher in PYY transgenic mice compared to wild types, albeit the difference was not 
significant, and there was no change in POMC expression observed between the chow-fed 
groups (Table 2). NPY and POMC expression were not different between high-fat fed groups 
(Table 2). 
 
3.5. PYY transgenic expression results in decreased body weight and adiposity in leptin 
deficient mice 
 As PYY transgenic mice were protected against the development of diet-induced 
obesity, we were interested in determining the effect of PYY over-expression on a genetic 
model of obesity, using ob/ob mice. PYYtg/ob mice had a significantly lower body weight than 
ob/ob controls ( Fig. 2C). Similar to high-fat fed PYYtg mice, PYYtg/ob mice had significantly 
less white adipose tissue both in absolute terms (data not shown) and as a percent of body 
weight ( Fig. 2E) and an increased body temperature (Fig. 2I) than ob/ob controls, in the 
absence of changes in basal and fasting-induced food intake ( Table 1, Fig. 3C). Consistent 
with the lack of effect of the PYY transgene on food intake, water intake of PYYtg/ob mice 
was no different from that of ob/ob mice ( Table 1). However, PYYtg/ob mice showed 
significantly lower serum triglyceride levels than ob/ob controls ( Table 1), in keeping with the 
associated decrease in fat mass (Fig. 2E). This demonstrates that PYYtg mice have reduced 
weight and body fat via effects independent of food intake. 
 
3.6. PYYtg/ob mice exhibit improved glucose tolerance 
 In light of our previous findings that PYY ablation results in basal and glucose-
induced hyperinsulinemia and glucose intolerance (Boey et al., 2006b), we hypothesized that 
PYYtg mice would have improved glucose tolerance. Surprisingly, under conditions of chow- 
and high-fat feeding, fasting serum glucose levels were significantly higher in PYYtg 
compared to wild type mice ( Fig. 4A and B). However, serum glucose levels, glucose area 
under the curve and serum insulin levels during a glucose tolerance test were not significantly 
different between chow- or fat-fed transgenic and wild type animals on a lean background 
(Fig. 4A + B, D + E, and G + H). 
 As PYYtg/ob mice showed decreased body weight and fat mass, we 
hypothesized that PYY over-expression may have additional beneficial effects on the 
hypeinsulinemia, hyperglycemia and insulin resistance exhibited by ob/ob mice. In keeping 
with this, PYYtg/ob mice had significantly lower fasting serum glucose levels and were 
markedly more glucose tolerant than ob/ob animals during the glucose tolerance test ( Fig. 
4C + F). PYYtg/ob mice also exhibited lower serum insulin levels for the duration of the 
glucose tolerance test ( Fig. 4I). 
eﬀects on basal and fasting-induced food intake mea-
sured at 11–12 weeks of age, nor significant changes in
NPY and POMC expression in the hypothalamic arcu-
ate nucleus, illustrating the importance of factors other
than energy intake in mediating and/or maintaining
anti-obesity eﬀects of PYY.
The reduced fat mass of PYY transgenic mice may be
explained by changes in the hypothalamo–pituitary–thy-
roid axis. Indeed, unlike wild type mice, which showed a
decrease in TRH expression in the arcuate nucleus in
response to high fat diet, PYY transgenic mice on a high
fat diet showed no such inhibition of hypothalamic
TRH levels. This suggests that PYYtg animals retain
normal activity of the hypothalamo–pituitary–thyroid
axis during high fat feeding, which may be causally asso-
ciated with the significantly increased temperature
and reduced brown adipose tissue mass seen in these
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Fig. 4. Glucose homeostasis in PYYtgmice. (A–C) Changes in serum glucose levels after ip glucose injection (1.0 mg/kg) in 24 h fasted chow- or high
fat-fed male wild type and PYYtg mice and in PYYtg/ob and ob/ob mice. (D–F) Areas under the glucose response curves (AUC). (G–I) Changes in
serum insulin levels after ip glucose injection (1.0 mg/kg) in 24 h fasted chow- or high fat-fed male wild type and PYY transgenic mice and PYYtg/ob
and ob/ob mice. Data represent means ± SEM of 8–12 mice per group. *p < 0.05 versus the comparison shown by horizontal bar.
Table 2
Thyrotropin releasing hormone (TRH) mRNA expression in the
paraventricular nucleus of the hypothalamus and neuropeptide Y
(NPY) and proopiomelanocortin (POMC) mRNA expression in the
arcuate nucleus of the hypothalamus in wild type and PYYtg mice
Wild type PYYtg
TRH
Chow 100% ± 8.2 107.4% ± 8.9
High fat 73.6% ± 8.4* 103.6% ± 12.4!
NPY
Chow 100% ± 8.0 116% ± 6.5
High fat 87.6% ± 9.6 93.4% ± 9.3
POMC
Chow 100% ± 9.2 91.2% ± 12.1
High fat 90.6% ± 13.1 83.7% ± 3.2
Data represents means ± SEM of 4–5 mice per group.
* p < 0.05 versus chow-fed wild type mice.
! p < 0.05 versus high-fat fed wild type mice.
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4. Discussion 
 This study demonstrates the important role PYY has in the regulation of energy 
homeostasis, since even only modestly increased expression of PYY can significantly reduce 
body weight and/or adiposity under diet- and genetically-induced obesogenic conditions. This 
is associated with significantly improved glucose tolerance in genetically obese ob/ob mice, 
changes in the hypothalamo–pituitary–thyroid axis and increased thermogenic activity. 
Resistance to diet- or genetically-induced obesity in PYYtg mice occurred in the absence of 
significant effects on basal and fasting-induced food intake measured at 11–12 weeks of age, 
nor significant changes in NPY and POMC expression in the hypothalamic arcuate nucleus, 
illustrating the importance of factors other than energy intake in mediating and/or maintaining 
anti-obesity effects of PYY. 
 The reduced fat mass of PYY transgenic mice may be explained by changes in the 
hypothalamo–pituitary–thyroid axis. Indeed, unlike wild type mice, which showed a decrease 
in TRH expression in the arcuate nucleus in response to high fat diet, PYY transgenic mice 
on a high fat diet showed no such inhibition of hypothalamic TRH levels. This suggests that 
PYYtg animals retain normal activity of the hypothalamo–pituitary–thyroid axis during high fat 
feeding, which may be causally associated with the significantly increased temperature and 
reduced brown adipose tissue mass seen in these animals. This finding is in keeping with a 
recent report that PYY3-36 stimulates thyrotropin (thyroid stimulating hormone) secretion by 
direct action on the pituitary gland in vitro, and significantly increases circulating thyroptropin 
levels after ip injection in fasted rats ( Oliveira et al., 2006). Alternatively, it is possible that the 
increased TRH expression observed in PYYtg mice was a consequence rather than a cause 
of their resistance to diet-induced obesity: because these mice were resistant to increased 
adiposity with high-fat feeding, there was no compensatory increase in activity of the 
thyrotropic axis and circulating free T4 levels, which therefore did not down-regulate TRH 
levels in the hypothalamus as part of the negative feedback loop. Both potential pathways are 
consistent with previous studies showing that thyroid hormones increase thermogenesis and 
decrease brown and white adipose tissue mass ( Ribeiro et al., 2001 and Silva and Larsen, 
eﬀects on basal and fasting-induced food intake mea-
sured at 11–12 weeks of age, nor significant changes in
NPY and POMC expression in the hypothalamic arcu-
ate nucleus, illustrating the importance of factors other
than energy intake in mediating and/or maintaining
anti-obesity eﬀects of PYY.
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Fig. 4. Glucose homeostasis in PYYtgmice. (A–C) Changes in serum glucose levels after ip glucose injection (1.0 mg/kg) in 24 h fasted chow- or high
fat-fed male wild type and PYYtg mice and in PYYtg/ob and ob/ob mice. (D–F) Areas under the glucose response curves (AUC). (G–I) Changes in
serum insulin levels after ip glucose injection (1.0 mg/kg) in 24 h fasted chow- or high fat-fed male wild type and PYY transgenic mice and PYYtg/ob
and ob/ob mice. Data represent means ± SEM of 8–12 mice per group. *p < 0.05 versus the comparison shown by horizontal bar.
Table 2
Thyrotropin releasing hormone (TRH) mRNA expression in the
paraventricular nucleus of the hypothalamus and neuropeptide Y
(NPY) and proopiomelanocortin (POMC) mRNA expression in the
arcuate nucleus of the hypothalamus in wild type and PYYtg mice
Wild type PYYtg
TRH
Chow 100% ± 8.2 107.4% ± 8.9
High fat 73.6% ± 8.4* 103.6% ± 12.4!
NPY
Chow 100% ± 8.0 116% ± 6.5
High fat 87.6% ± 9.6 93.4% ± 9.3
POMC
Chow 100% ± 9.2 91.2% ± 12.1
High fat 90.6% ± 13.1 83.7% ± 3.2
Data represents means ± SEM of 4–5 mice per group.
* p < 0.05 versus chow-fed wild type mice.
! p < 0.05 versus high-fat fed ild type mice.
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1983). It is also possible that the apparent increase in energy expenditure in fat-fed PYYtg 
mice compared to wild type mice (indicated by reduced adiposity in the presence of no 
significant change in food intake) may be due to increases in free T3 concentrations within 
peripheral tissues rather than changes in circulating free T4 levels as were measured in this 
study ( Silva and Larsen, 1983). 
 In addition to reduced body weight, reduced white adipose tissue mass, reduced 
circulating triglyceride levels and a tendency to higher body temperatures in the absence of 
effects on basal- or fasting-induced food intake, PYYtg/ob mice were significantly more 
glucose tolerant than ob/ob controls, with lower serum insulin levels observed for the duration 
of a glucose tolerance test. This is consistent with our previous findings that PYY knockout 
animals are equally glucose tolerant but hyperinsulinemic after a glucose challenge ( Boey et 
al., 2006b) and further supports an important long-term role for PYY in regulating glucose 
homeostasis. Moreover, as low PYY levels are associated with increased insulin secretion 
and insulin resistance in humans (Boey et al., 2006a), enhanced expression of PYY may 
improve glucose homeostasis and insulin sensitivity, in keeping with findings from others ( 
van den Hoek et al., 2004 and Vrang et al., 2006). 
 Notably, chow-fed PYY transgenic animals displayed significantly lower serum IGF-1 
levels than wild types, consistent with data from PYY knockout mice which show significantly 
increased serum IGF-1 levels and increased GHRH mRNA expression in the ventromedial 
hypothalamus (VMH) ( Boey et al., 2006b). These data – together with findings that growth 
hormone and IGF-1 enhance PYY expression ( Gomez et al., 1996 and Wang et al., 2004) – 
support the notion that PYY is involved in a feedback loop to inhibit the somatotropic axis. 
 PYY transgenic mice showed no significant decrease in basal or fasting-induced food 
intake when investigated at 11–12 weeks of age. It was recently shown that whereas 
continuous infusion of PYY3-36 to obese or diabetic rodent models via osmotic mini pumps 
results in transient reductions in food intake that persist for only 4–6 days (Adams et al., 
2006 and Pittner et al., 2004), intermittent administration of PYY3-36 to lean or diet-induced 
obese rats results in reductions in food intake that are sustained for the entire 10–21-day 
study period (Chelikani et al., 2006 and Chelikani et al., 2007). It is possible that early PYY-
induced reductions in food intake and energy balance may induce compensatory responses 
to help restore energy homeostasis, or that long-term administration of PYY leads to 
desensitization and downregulation of Y receptors. Therefore it cannot be excluded that our 
PYY transgenic animals may have had transient reductions in food intake in early life (e.g. 
before weaning), and that such anorexia may have led to reductions in body weight and/or 
adiposity that were maintained throughout the study. 
 The amount of PYY over-expression in our PYY transgenic animals was not as high 
as anticipated. However, our findings that only two founder animals were produced, one of 
which died, and the fact that we found a high frequency of fatalities in either gender of our 
PYYtg breeding pairs indicates that high endogenous PYY expression are disadvantageous 
during development. Hence, it is likely that only PYY transgenic mice that had modest over-
expression of PYY survived. This is supported by a recent study showing that CMV driven 
PYY over-expression resulted in neural tube defects in mice, a common cause of congenital 
malformation that leads to infant mortality ( Yuzuriha et al., 2007). Nonetheless, our studies 
demonstrate that even the mild increases in PYY expression observed in our PYY transgenic 
mice were sufficient to induce significant effects on body weight, adiposity, thermogenesis, 
activity of the hypothalamo–pituitary–thyroid axis, glucose tolerance and IGF-1 levels. 
Moreover, the fact that many of the phenotypic characteristics observed in our PYYtg mice 
were opposite to effects seen in PYY−/− mice (e.g. fat mass, serum insulin levels in response 
to glucose as well as serum IGF-1 levels) provides further support that the phenotype 
observed in our PYYtg mice is due to PYY over-expression. Increased PYY expression is 
evident in the pancreatic islets of high-fat fed PYY transgenic animals but not in chow-fed 
PYY transgenics suggesting that high fat feeding evokes an increase in endogenous PYY 
production, which may help to explain why the effects of our PYY transgene were more 
apparent under conditions of high fat feeding. Alternatively, PYY produced in these mice may 
be rapidly degraded in vivo in compensation for the increased rates of production ( Shechter 
et al., 2005). 
 In summary, we show that PYYtg mice are protected against the development of 
obesity in high-fat fed and ob/ob mice in the absence of effects on basal- or fasting-induced 
food intake when measured at 11–12 weeks of age. Similarly, PYYtg/ob mice exhibited 
decreased bodyweight, fat mass and improved glucose tolerance associated with decreased 
Boey	  et	  al.:	  Neuropeptides	  42	  (2008)	  19-­‐30	  	  
insulin levels. This is consistent with data from PYY knockout mice generated in our 
laboratory, which were hyperinsulinemic and became fatter than controls with aging or high 
fat feeding, in the absence of changes in food intake measured at 11–12 weeks of age ( Boey 
et al., 2006b). Additionally, a recent PYY knockout mouse model was also shown to exhibit 
an obese phenotype, albeit that model also showed significant basal and fasting-induced 
hyperphagia when measured at 8 weeks of age (Batterham et al., 2006). Together, our 
findings support the possibility that measures to increase PYY production and secretion may 
be therapeutic for the treatment of obesity, not only via effects on appetite regulation but 
possibly also on energy efficiency. 
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